Market Overview - The A-share market showed mixed performance on July 4, with the Shanghai Composite Index rising slightly by 0.05% to 3462.99, while the Shenzhen Component and ChiNext Index fell by 0.35% and 0.31% respectively [2][3] - The total trading volume reached 1.77 billion hands, with a turnover of 190.16 billion [4] Sector Performance - The steel sector saw a collective rise, with notable stocks like Liugang and Linggang hitting the daily limit up [10][11] - The banking sector also experienced gains, with several banks, including Zheshang Bank and Shanghai Bank, reaching new highs [16][17] - The pharmaceutical sector remained strong, with stocks like Hotgen and Guangsheng rising over 10% [12][13] Notable Stocks - Hangzhou Garden surged to the daily limit within two minutes of opening, while Nanling Technology also hit the limit up [20][22] - In the steel sector, Liugang shares increased by 10.02%, and Linggang shares rose by 10.16% [11] - In the pharmaceutical sector, Hotgen's stock price increased by 14.57%, and Guangsheng's by 10.75% [13] Industry Insights - The Ministry of Industry and Information Technology emphasized the need for orderly competition in the photovoltaic industry, aiming to improve product quality and phase out outdated capacity [8] - A report indicated that the photovoltaic industry may face weakening demand in the second half of the year, prompting leading companies to reduce production to improve supply-demand dynamics [9]

Group 1 - The innovative drug sector is experiencing a strong opening, with Selin Medical (603716) achieving a four-day consecutive rise [1] - Tainkang (301263) and Zhongyuan Qihua (600645) opened high with a 6% increase [1] - Other companies such as Guangshengtang (300436), Weiming Pharmaceutical (002581), and Changchun High-tech (000661) also saw significant opening gains [1] Group 2 - Dark pool funds are flowing into these stocks, indicating increased investor interest [2]

Core Viewpoint - The announcement highlights the abnormal trading fluctuations of the convertible bond "塞力转债," which experienced a cumulative price increase of over 30% over three consecutive trading days, prompting a disclosure to investors regarding potential valuation risks [2][8]. Group 1: Convertible Bond Trading Situation - "塞力转债" recorded a closing price of 175.078 yuan per bond as of July 3, 2025, representing a premium of 75.08% over the face value and a conversion premium rate of 9.65% [2][8]. - The bond experienced a cumulative price increase of over 30% from July 1 to July 3, 2025, qualifying as an abnormal trading situation under the Shanghai Stock Exchange regulations [2][8]. Group 2: Company Operations and Major Events - The company confirmed that its production and operational activities are normal, with no significant changes in market conditions or industry policies that could affect the bond's trading price [9]. - There are no undisclosed major events related to asset restructuring, share issuance, or significant transactions that could impact the company's stock or bond prices [10]. Group 3: Share Pledge and Control - The controlling shareholder,赛海科技, holds 21,642,540 shares, representing 11.33% of the total share capital, and has recently unpledged 6,700,000 shares while pledging 6,000,000 shares, resulting in a total of 15,100,000 shares pledged [19][20]. - The actual controller, 温伟, holds 9,634,208 shares, representing 5.04% of the total share capital, and has similarly unpledged 3,850,000 shares while pledging 3,000,000 shares, leading to a total of 8,300,000 shares pledged [20].

Group 1 - The brain-computer interface (BCI) sector has seen significant advancements since 2025, with related stocks experiencing substantial increases, such as Saily Medical up 165.37% and Innovative Medical up 92.46% as of July 3 [1] - The A-share BCI sector has an overall increase of 49.1% this year, indicating a strong market sentiment towards this industry [1] - Policy support has been a driving force, with cities like Beijing and Shanghai launching five-year action plans for BCI development, aiming to cultivate innovative enterprises and achieve clinical application of BCI products by 2030 [1][2] Group 2 - The establishment of China's first BCI industrial cluster in Shanghai marks a significant step in the domestic BCI landscape, with the new facility expected to be operational within the year [2] - The stock market has reacted positively, with multiple BCI-related stocks experiencing consecutive gains, such as Saily Medical and Jihua Group achieving three consecutive trading limits [2] - The BCI theme index in A-shares has risen by 4.96% over the past month, reflecting ongoing investor interest [2] Group 3 - Companies are increasingly engaging with investors regarding BCI developments, with Chengyitong announcing a dual-track strategy in invasive and non-invasive BCI technologies [3] - Chengyitong plans to release three prototypes of neuro-rehabilitation devices integrating BCI technology by July 2024 [3] - Other companies, such as Chengdu Huamei and Pulite, are also exploring BCI applications, focusing on signal processing hardware and high-performance materials, respectively [3]

Core Viewpoint - The announcement details the pledge and unpledge of shares by the controlling shareholder and actual controller of Saily Medical Technology Group Co., Ltd, indicating a significant portion of their holdings are pledged, which may impact investor perception and company liquidity [1][2][3]. Summary by Sections 1. Share Pledge and Unpledge Overview - The controlling shareholder, Saihai (Shanghai) Health Technology Co., Ltd, holds 21,642,540 shares, representing 11.33% of the total share capital. Recently, 6,700,000 shares were unpledged, followed by the pledge of 6,000,000 shares, resulting in a total of 15,100,000 shares pledged, which is 69.77% of their holdings and 7.91% of the total share capital [1][2]. - The actual controller, Mr. Wen Wei, holds 9,634,208 shares, or 5.04% of the total share capital. He unpledged 3,850,000 shares and then pledged 3,000,000 shares, leading to a total of 8,300,000 shares pledged, which is 86.15% of his holdings and 4.35% of the total share capital [2][3]. 2. Detailed Pledge and Unpledge Data - Saihai Technology unpledged 6,700,000 shares, accounting for 30.96% of their holdings and 3.51% of the total share capital, with the unpledge occurring on July 1 and July 2, 2025. After the transaction, they have 15,100,000 shares pledged [3][4]. - Mr. Wen Wei unpledged 3,850,000 shares, which is 39.96% of his holdings and 2.02% of the total share capital, with the unpledge occurring on July 1, 2025. He now has 8,300,000 shares pledged [2][3]. 3. Cumulative Pledge Situation - As of the announcement date, the total pledged shares by both Saihai Technology and Mr. Wen Wei amount to 23,400,000 shares, which is 74.82% of their combined holdings and 12.25% of the total share capital [4][5]. - The cumulative pledge situation indicates that Saihai Technology has 15,100,000 shares pledged, while Mr. Wen Wei has 8,300,000 shares pledged, reflecting a significant portion of their total holdings [4][5]. 4. Future Pledge Obligations - The future pledge obligations for Saihai Technology and Mr. Wen Wei amount to 9,000,000 shares, which is 28.78% of their holdings and a corresponding 3.72% of the total share capital, with a financing balance of 20.11 million yuan [5][6].

证券代码：603716 证券简称：塞力医疗 公告编号：2025-059 债券代码：113601 债券简称：塞力转债 塞力斯医疗科技集团股份有限公司 （一）可转换公司债券发行情况 经中国证券监督管理委员会（证监许可【2020】1033号）核准，公司于2020 年8月21日公开发行了543.31万张可转换公司债券，每张面值100元，发行总额 第二年0.80%，第三年1.00%，第四年1.50%，第五年2.50%，第六年3.00%。 （二）可转换公司债券上市情况 经上海证券交易所自律监管决定书【2020】306号文同意，公司发行总额为 债券简称"塞力转债"，债券代码"113601"。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? "塞力转债"于2025年7月1日、7月2日、7月3日连续3个交易日收盘价格 涨幅偏离值累计超过30%，根据《上海证券交易所可转换公司债券交易实施细则》 的相关规定，属于可转债交易异常波动情况。 ? 截至2025年7月3日收盘，"塞力转债"收盘价格为175.078元/张，相对 于票面价格 ...

| 证券代码：603716 | 证券简称：塞力医疗 | 公告编号：2025-059 | | --- | --- | --- | | 债券代码：113601 | 债券简称：塞力转债 | | 塞力斯医疗科技集团股份有限公司 关于"塞力转债"交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： "塞力转债"于2025年7月1日、7月2日、7月3日连续3个交易日收盘价格 涨幅偏离值累计超过30%，根据《上海证券交易所可转换公司债券交易实施细则》 的相关规定，属于可转债交易异常波动情况。 截至2025年7月3日收盘，"塞力转债"收盘价格为175.078元/张，相对 于票面价格溢价75.08%，转股溢价率9.65%。敬请广大投资者注意当前估值风险， 理性投资。 经公司自查，并向控股股东赛海（上海）健康科技有限公司（以下简称 "赛海科技"）及实际控制人温伟先生发函核实，截至本公告披露日，控股股东 及实际控制人不存在应披露而未披露的重大信息，包括但不限于重大资产重组、 股份发行、重大交易类事项、业务重组、股份回购、 ...

| 证券代码：603716 | 证券简称：塞力医疗 | 公告编号：2025-058 | | --- | --- | --- | | 债券代码：113601 | 债券简称：塞力转债 | | 塞力斯医疗科技集团股份有限公司 关于控股股东、实际控制人部分股份 解除质押及股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 塞力斯医疗科技集团股份有限公司（以下简称"公司"）控股股东赛海 （上海）健康科技有限公司（以下简称"赛海科技"）持有公司 21,642,540 股 无限售条件流通股股票，占公司总股本的 11.33%（截至 2025 年 6 月 30 日总股 本，下同）。近日，赛海科技将其中 6,700,000 股股份办理了解除质押登记手续， 后将 6,000,000 股股份办理了质押登记手续，本次新增质押为替换性质押。相关 手续办理完毕后，赛海科技累计质押公司股份 15,100,000 股，占其持有公司股 份比例为 69.77%，占公司总股本比例为 7.91%。 公司实际控制人温伟先生持有公司股份 9,6 ...

Core Viewpoint - The company announced that its convertible bond "Saili Convertible Bond" experienced an abnormal trading fluctuation, with a cumulative closing price increase exceeding 30% over three consecutive trading days from July 1 to July 3, 2025 [1] Group 1 - The company's production and operational activities are normal, with no significant adjustments in market environment or industry policies [1] - The internal production and operational order of the company is stable [1] - The controlling shareholder and actual controller of the company do not have any undisclosed significant information that should have been disclosed [1]

New Stock Offerings - Jichuan Pharmaceutical (600566) has a tender offer period from June 18, 2025, to July 17, 2025[1] - *ST Yazhen (603389) has a tender offer period from June 10, 2025, to July 9, 2025[1] - Zhongcheng Tui (300208) has 11 trading days remaining until the last trading day[1] Delisting and Trading Reminders - Tui Shi Jin Gang (600190) has 11 trading days remaining until the last trading day[1] - Hengli Tui (000622) is in the delisting arrangement period with 8 trading days remaining[1] - Tui Shi Jiu You (600462) has 7 trading days remaining until the last trading day[1] Market Volatility - Beifang Changlong (301357) reported severe abnormal fluctuations[1] - Multiple companies, including Jichuan Pharmaceutical and *ST Yazhen, are under scrutiny for trading anomalies[1]